Shared on29 Jul 25Fair value Increased 9.95%
Exelixis’ consensus price target has risen to $46.05, primarily driven by positive Phase 3 STELLAR-303 results for zanzalintinib, which boost expectations for regulatory approval and over $1B peak sales potential, while some analysts remain cautious on valuation and Cabometyx’s long-term outlook. Analyst Commentary Bullish analysts cite positive topline results from the STELLAR-303 Phase 3 trial, where zanzalintinib (Zanza) in combination with atezolizumab demonstrated statistically significant improvement in overall survival versus comparator regimens in non-microsatellite instability-high metastatic colorectal cancer.
Shared on07 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on30 Apr 25Fair value Decreased 1.33%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 2.38%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 8.81%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 0.24%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Decreased 7.80%
AnalystConsensusTarget has decreased future PE multiple from 14.8x to 11.9x.